Published in EMBO J on May 17, 2007
GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci (2011) 1.99
Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry (2016) 1.38
GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci (2014) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry (2009) 1.14
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci (2012) 1.13
GSK-3beta is required for memory reconsolidation in adult brain. PLoS One (2008) 1.11
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis (2008) 1.10
Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet (2010) 1.01
GSK3beta in ethanol neurotoxicity. Mol Neurobiol (2009) 1.01
Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis (2011) 0.94
A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum Mol Genet (2010) 0.93
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest (2010) 0.92
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3. Int J Alzheimers Dis (2011) 0.85
GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ (2014) 0.82
GSK3β expression and phosphorylation during neuronal maturation in the rat dorsal root ganglion. Int J Clin Exp Med (2015) 0.81
GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner. PLoS One (2011) 0.80
Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. Acta Neuropathol Commun (2016) 0.80
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. PLoS One (2013) 0.79
The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. Mol Cancer Ther (2011) 0.78
GSK-3β and MMP-9 Cooperate in the Control of Dendritic Spine Morphology. Mol Neurobiol (2016) 0.78
Amyloid-beta induced CA1 pyramidal cell loss in young adult rats is alleviated by systemic treatment with FGL, a neural cell adhesion molecule-derived mimetic peptide. PLoS One (2013) 0.75
Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. Acta Neuropathol Commun (2017) 0.75
Wnt signaling and cancer. Genes Dev (2000) 18.53
beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 12.97
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell (1996) 10.40
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37
The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci (2004) 7.92
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Control of memory formation through regulated expression of a CaMKII transgene. Science (1996) 7.56
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 6.45
Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J (1990) 6.23
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
Conditional control of gene expression in the mouse. Nat Rev Genet (2001) 5.30
Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem (1998) 5.09
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome (1997) 4.15
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J (1994) 3.62
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol (2006) 3.17
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85
Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci (2000) 2.70
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci (2003) 2.54
Role of tau protein in both physiological and pathological conditions. Physiol Rev (2004) 2.44
Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci U S A (1995) 2.42
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods (1997) 2.04
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med (2002) 1.85
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80
Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A (1998) 1.71
Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci (2002) 1.66
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett (2002) 1.29
Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett (1999) 1.23
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci (2001) 1.22
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci (2005) 1.18
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci (2005) 1.10
Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.08
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun (2003) 1.03
Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci (2004) 1.02
Inducible gene expression in the nervous system of transgenic mice. Annu Rev Neurosci (1998) 1.02
Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure. Neuroscience (2004) 1.01
Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets (2006) 0.93
Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. J Alzheimers Dis (1999) 0.92
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 2.65
Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance. Cell (2013) 2.43
Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res (2007) 2.22
Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem (2004) 1.97
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain (2010) 1.77
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci (2004) 1.61
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry (2010) 1.55
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex (2004) 1.48
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Biomagnification study on organochlorine compounds in marine aquaculture: the sea bass (Dicentrarchus labrax) as a model. Environ Sci Technol (2003) 1.44
Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex (2004) 1.43
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol (2004) 1.39
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J (2009) 1.33
Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem (2006) 1.33
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol (2011) 1.32
The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev (2004) 1.32
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev (2002) 1.30
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex (2008) 1.26
Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A (2007) 1.23
Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci (2006) 1.21
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology (2007) 1.19
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci (2005) 1.18
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2011) 1.17
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
Serotonin modulation of cortical neurons and networks. Front Integr Neurosci (2013) 1.15
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol (2007) 1.14
A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex (2004) 1.13
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex (2003) 1.12
In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex (2004) 1.11
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J (2003) 1.11
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci (2005) 1.10
Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs (2013) 1.10
Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci (2010) 1.10
Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem (2005) 1.09
Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex (2004) 1.09
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 1.08
Comparing illicit drug use in 19 European cities through sewage analysis. Sci Total Environ (2012) 1.07
The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology (2005) 1.06
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol Psychiatry (2011) 1.05
The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry (2008) 1.05
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol (2004) 1.04
A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol (2005) 1.04
GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 1.04
Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci (2002) 1.03
Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol (2004) 1.03
Multi-class determination of around 50 pharmaceuticals, including 26 antibiotics, in environmental and wastewater samples by ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr A (2011) 1.02
Strategies for producing faster acting antidepressants. Drug Discov Today (2005) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging (2005) 1.02
Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl) (2012) 1.01
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J (2013) 1.00